ImmunityBio’s ANKTIVA Drives 700% Surge in Revenue and Achieves First Global NSCLC Approval
Record Growth: Revenue and Unit Sales Soar on Strong ANKTIVA Adoption
ImmunityBio (NASDAQ: IBRX) revealed preliminary 2025 financial results, reporting a remarkable $113 million in net product revenue—a staggering 700% year-over-year increase. The latest quarter alone saw revenues climb to $38.3 million, up 20% from the previous quarter and up 431% from the same period the prior year. ANKTIVA’s unit sales volume echoed this breakout performance, rising an impressive 750% for the full year as adoption accelerated globally.
| Period | Net Product Revenue (in $ millions) | Change YoY (%) | Change QoQ (%) | Unit Sales Growth (%) |
|---|---|---|---|---|
| Full Year 2025 | 113.00 | 700 | - | 750 |
| Q4 2025 | 38.30 | 431 | 20 | 54 (QoQ) |
| Q3 2025 | 31.80 | - | - | - |
| Q4 2024 | 7.21 | - | - | - |
International Milestones: ANKTIVA’s Landmark Approvals Expand Market
ImmunityBio’s momentum isn’t confined to financial figures. The Saudi Food and Drug Authority (SFDA) approved ANKTIVA in combination with immune checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC) patients who failed standard therapies—its first global approval for this indication, and notably, the world’s first for an IL-15 superagonist paired with checkpoint therapy. This approval paves the way for subcutaneous administration and marks a key strategic step in expanding ANKTIVA’s usage beyond the U.S. and Europe.
The SFDA also greenlit ANKTIVA for use with BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS), further validating its therapeutic potential and adding to ImmunityBio’s roster of regulatory wins across multiple geographies.
Cash Reserves and Clinical Trial Progress Position ImmunityBio for Sustained Growth
As of December 31, 2025, ImmunityBio reported holding approximately $242.8 million in cash, cash equivalents, and marketable securities, providing a solid base to support ongoing innovation and market expansion. The company’s Phase 2b QUILT-2.005 trial is ahead of internal enrollment goals, targeting full enrollment in the first half of 2026. This advances the company’s first-line NMIBC program and reinforces its commitment to redefining cancer care standards.
Takeaway: Regulatory Wins and Execution Set Stage for Broader Immunotherapy Impact
ImmunityBio’s 2025 performance showcases a company firing on all cylinders—dramatic revenue and unit sales growth, clinical advancement, and unprecedented regulatory approvals. Investors and industry watchers should watch how continued execution, geographic market access, and ANKTIVA’s expanding clinical footprint position ImmunityBio in the rapidly evolving immunotherapy space.
Note: These financial figures are based on preliminary estimates and may be updated in ImmunityBio’s final annual report filings.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI